Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients

Deep News

01/05

According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's "2025 Semi-Annual Report," patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.

Furthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.

Subsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1162243825"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162243825\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162243825?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162243825","market":"us","top_or_hot":-1,"title":"Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients","media":"Deep News","content":"<p>According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.</p>\n<p>Furthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.</p>\n<p>Subsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly: PD-L1/VEGF Bispecific Antibody's Solid Tumor Indication Phase IIa and Colorectal Cancer Indication Phase IIb Trials Currently Enrolling Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-05 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.</p>\n<p>Furthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.</p>\n<p>Subsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"","article_id":"1162243825","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162243825","pubTimestamp":1767622319,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600535":"天士力","BK0183":"MSCI概念","BK0028":"国家队","BK0239":"医药制造","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK0188":"融资融券","BK0196":"行业龙头","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4023":"应用软件","BK0012":"证金概念","PD":"PagerDuty, Inc."},"translate_title":"天士力：PD-L1/VEGF双特异性抗体实体瘤适应症IIa期和结直肠癌适应症IIb期试验目前正在入组患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600535":1,"PD":1},"content_text":"According to a response on the investor interaction platform on January 5th, Tasly Pharmaceutical Group Co.,Ltd. stated that, as per the company's \"2025 Semi-Annual Report,\" patient enrollment is currently underway for the Phase IIa clinical trial of the PD-L1/VEGF bispecific antibody for solid tumor indications and the Phase IIb trial for colorectal cancer indications.\nFurthermore, the clinical trial for the Recombinant Human Fibroblast Growth Factor 21 Injection has advanced to the Ib phase.\nSubsequent research and development progress will be announced by the company in accordance with the relevant information disclosure regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}